Publications

  1. Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 2017 Feb 16 [Epub ahead of print]
    View PubMed
  2. Ertz-Archambault N, Kosiorek H, Taylor GE, Kelemen K, Dueck A, Castro J, Marino R, Gauthier S, Finn L, Sproat LZ, Palmer J, Mesa RA, Al-Kali A, Foran J, Tibes R. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 2017 Feb 02 [Epub ahead of print]
    View PubMed
  3. Tondato F, Bazzell J, Schwartz L, Mc Donald BW, Fisher R, Anderson SS, Galindo A, Dueck AC, Scott LR. Safety and interaction of patients with implantable cardiac defibrillators driving a hybrid vehicle. Int J Cardiol 2017 Jan 15; 227:318-324 Epub 2016 Nov 09
    View PubMed
  4. Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins RB, Sicotte H, Kollmeyer TM, O'Neill BP, Elmquist W, Hoxworth JM, Frakes D, Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol 2017 Jan; 19 (1):128-137 Epub 2016 Aug 08
    View PubMed
  5. Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Dohner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica 2017 Jan; 102 (1):85-93 Epub 2016 Aug 18
    View PubMed
  6. Dueck AC. A statistician's perspective on a long time to publish. Lancet Haematol 2017 Jan; 4 (1):e12 Epub 2016 Dec 02
    View PubMed
  7. Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, te Boekhorst PAW, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Dohner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group Haematologica 2017; 102 (1):85-93
  8. Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, Petricoin EF 3rd, Zeuner A, Iancu-Rubin C, Weinberg R, Hoffman R, Mascarenhas J, Migliaccio AR. Preclinical rationale for TGF-beta inhibition as a therapeutic target for the treatment of myelofibrosis. Exp Hematol 2016 Dec; 44 (12):1138-1155.e4 Epub 2016 Aug 31
    View PubMed
  9. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14
    View PubMed
  10. Chang JM, Kosiorek HE, Dueck AC, Casey WJ, Rebecca AM, Mahabir R, Patel SH, Keole SR, Wong WW, Vargas CE, Halyard MY, Gray RJ, Wasif N, Stucky CH, Pockaj BA. Trends in mastectomy and reconstruction for breast cancer; a twelve year experience from a tertiary care center. Am J Surg 2016 Dec; 212 (6):1201-1210 Epub 2016 Sept 29
    View PubMed
  11. Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Mesa RA, Barbui T. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leuk Lymphoma 2016 Nov 10; 1-7 [Epub ahead of print]
    View PubMed
  12. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium, Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schurmann C, Smith AW, Soltys KM, Taphoorn MJ, Velikova G, Coens C. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 2016 Nov; 17 (11):e510-e514 Epub 2016 Oct 18
    View PubMed
  13. Padrnos L, Bennett R, Kosiorek H, Dueck AC, Northfelt D, Mikhael J, Tibes R, Khera N, Mesa RA. Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit. J Cancer Educ 2016 Oct 11 [Epub ahead of print]
    View PubMed
  14. Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 2016 Sep 8 Epub 2016 Sept 08
    View PubMed
  15. Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. J Natl Cancer Inst 2016 Aug; 108 (8) Epub 2016 Apr 20
    View PubMed
  16. Basch E, Dueck AC. Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data. Expert Opin Drug Discov 2016 Aug; 11 (8):753-8 Epub 2016 June 16
    View PubMed
  17. Caselli RJ, Dueck AC, Locke DE, Henslin BR, Johnson TA, Woodruff BK, Hoffman-Snyder C, Geda YE. Impact of Personality on Cognitive Aging: A Prospective Cohort Study. J Int Neuropsychol Soc 2016 Aug; 22 (7):765-76 Epub 2016 June 27
    View PubMed
  18. Basch E, Dueck AC. Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data Expert Opinion On Drug Discovery 2016 Aug; 11 (8):753-8
  19. Caselli RJ, Dueck AC, Locke DEC, Henslin BR, Johnson TA, Woodruff BK, Hoffman-Snyder C, Geda YE. Impact of personality on cognitive aging: a prospective cohort study Journal Of The International Neuropsychological Society 2016 Aug; 22 (7):765-76
  20. Rosenthal A, Kumar S, Hofmeister C, Laubach J, Vij R, Dueck A, Gano K, Stewart AK. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. Br J Haematol 2016 Jul; 174 (2):323-5 Epub 2015 Sept 25
    View PubMed
  21. Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer 2016 Jun 15; 122 (12):1888-96 Epub 2016 Apr 12
    View PubMed
  22. Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA. Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma. Dermatol Surg 2016 May; 42 (5):646-52
    View PubMed
  23. Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA. Risk factors predicting positive margins at primary wide local excision of cutaneous melanoma Dermatologic Surgery 2016 May; 42 (5):646-52
  24. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Dieras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib andor Trastuzumab Treatment Optimization Trial. J Clin Oncol 2016 Apr 01; 34 (10):1034-42 Epub 2015 Nov 23
    View PubMed
  25. Basch E, Rogak LJ, Dueck AC. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 2016 Apr; 38 (4):821-30 Epub 2016 Apr 02
    View PubMed
  26. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol 2016 Feb 20; 34 (6):557-65 Epub 2015 Dec 07
    View PubMed
  27. National Cancer Institute PRO-CTCAE Study Group, Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, Basch E. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 2016 Feb 19; 14:24
    View PubMed
  28. Dibaise JK, Islam RS, Dueck AC, Roarke MC, Crowell MD. Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying. Neurogastroenterol Motil 2016 Feb; 28 (2):196-205 Epub 2015 Oct 28
    View PubMed
  29. DiBaise JK, Patel N, Noelting J, Dueck AC, Roarke M, Crowell MD. The relationship among gastroparetic symptoms, quality of life, and gastric emptying in patients referred for gastric emptying testing. Neurogastroenterol Motil 2016 Feb; 28 (2):234-42 Epub 2015 Nov 07
    View PubMed
  30. Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, Geyer HL, McCallister A, Cotter M, Van Husen B, Harrison CN, Mesa RA. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer 2016 Feb 1; 122 (3):477-85 Epub 2015 Dec 15
    View PubMed
  31. Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol 2016 Jan 10; 34 (2):151-9 Epub 2015 Nov 23
    View PubMed
  32. Lakshminarayanan V, Supekar NT, Wei J, McCurry DB, Dueck AC, Kosiorek HE, Trivedi PP, Bradley JM, Madsen CS, Pathangey LB, Hoelzinger DB, Wolfert MA, Boons GJ, Cohen PA, Gendler SJ. MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. PLoS One 2016; 11 (1):e0145920 Epub 2016 Jan 20
    View PubMed
  33. Parikh P, Pockaj B, Wasif N, Halyard M, Wong W, Kosiorek HE, Dueck AC, Gray R. Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast. Ann Surg Oncol 2015 Dec; 22 Suppl 3:S516-21 Epub 2015 May 19
    View PubMed
  34. Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, Anderson KS, Pockaj BA. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma. Ann Surg Oncol 2015 Dec; 22 Suppl 3:S509-15 Epub 2015 May 22
    View PubMed
  35. Hu LS, Kelm Z, Korfiatis P, Dueck AC, Elrod C, Ellingson BM, Kaufmann TJ, Eschbacher JM, Karis JP, Smith K, Nakaji P, Brinkman D, Pafundi D, Baxter LC, Erickson BJ. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma. AJNR Am J Neuroradiol 2015 Dec; 36 (12):2242-9 Epub 2015 Sept 10
    View PubMed
  36. Linnaus ME, Dueck AC, Kosiorek HE, Gray RJ, Wasif N, Northfelt DW, Anderson KS, McCullough AE, Wong WW, Halyard MY, Patel SH, Pockaj BA. Regional recurrence in the era of sentinel lymph node biopsy. Am J Surg 2015 Dec; 210 (6):1155-60; discussion 1160-1 Epub 2015 Sept 28
    View PubMed
  37. National Cancer Institute PRO-CTCAE Study Group, Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 2015 Nov; 1 (8):1051-9
    View PubMed
  38. Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol 2015 Oct; 90 (10):864-70 Epub 2015 Sept 10
    View PubMed
  39. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbavaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Res 2015 Oct 01; 17 (1):133
    View PubMed
  40. Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 2015 Sep 22; 6 (28):26483-93
    View PubMed
  41. Ashfaq A, Kidwell JT, McGhan LJ, Dueck AC, Pockaj BA, Gray RJ, Bagaria SP, Wasif N. Validation of a gastric cancer nomogram using a cancer registry. J Surg Oncol 2015 Sep; 112 (4):377-80 Epub 2015 Aug 14
    View PubMed
  42. Garvey EM, Senior DA, Pockaj BA, Wasif N, Dueck AC, McCullough AE, Ocal IT, Gray RJ. Rates of residual disease with close but negative margins in breast cancer surgery. Breast 2015 Aug; 24 (4):413-7 Epub 2015 Apr 04
    View PubMed
  43. Alliance for Clinical Trials in Oncology, Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA. Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 2015 Jul; 26 (7):1971-7 Epub 2015 Mar 07
    View PubMed
  44. Gowin K, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leuk Res 2015 Jul; 39 (7):684-8 Epub 2015 Apr 17
    View PubMed
  45. Caselli RJ, Marchant GE, Hunt KS, Henslin BR, Kosiorek HE, Langbaum J, Robert JS, Dueck AC. Predictive testing for Alzheimer's disease: suicidal ideation in healthy participants. Alzheimer Dis Assoc Disord 2015 Jul-Sep; 29 (3):252-4
    View PubMed
  46. Padrnos L, Dueck AC, Scherber R, Glassley P, Stigge R, Northfelt D, Mikhael J, Aguirre A, Bennett RM, Mesa RA. Quality of life and disease understanding: impact of attending a patient-centered cancer symposium. Cancer Med 2015 Jun; 4 (6):800-7 Epub 2015 Jan 30
    View PubMed
  47. Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK. Phase IbII trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol 2015 Apr; 169 (2):219-27 Epub 2015 Feb 13
    View PubMed
  48. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2015 Mar 01; 33 (7):701-8 Epub 2015 Jan 20
    View PubMed
  49. Etzioni DA, Wasif N, Dueck AC, Cima RR, Hohmann SF, Naessens JM, Mathur AK, Habermann EB. Association of hospital participation in a surgical outcomes monitoring program with inpatient complications and mortality. JAMA 2015 Feb 3; 313 (5):505-11
    View PubMed
  50. Caselli RJ, Dueck AC, Locke DE, Baxter LC, Woodruff BK, Geda YE. Sex-based memory advantages and cognitive aging: a challenge to the cognitive reserve construct? J Int Neuropsychol Soc 2015 Feb; 21 (2):95-104 Epub 2015 Feb 09
    View PubMed
  51. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediators Inflamm 2015; 2015:284706 Epub 2015 Oct 11
    View PubMed
  52. Hu LS, Ning S, Eschbacher JM, Gaw N, Dueck AC, Smith KA, Nakaji P, Plasencia J, Ranjbar S, Price SJ, Tran N, Loftus J, Jenkins R, O'Neill BP, Elmquist W, Baxter LC, Gao F, Frakes D, Karis JP, Zwart C, Swanson KR, Sarkaria J, Wu T, Mitchell JR, Li J. Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. PLoS One 2015; 10 (11):e0141506 Epub 2015 Nov 24
    View PubMed
  53. Caselli RJ, Langbaum J, Marchant GE, Lindor RA, Hunt KS, Henslin BR, Dueck AC, Robert JS. Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc 2014 Oct; 89 (10):1389-96 Epub 2014 Aug 26
    View PubMed
  54. Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer 2014 Sep 09; 111 (6):1065-71 Epub 2014 Aug 12
    View PubMed
  55. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014 Sep; 106 (9) Epub 2014 Sept 29
    View PubMed
  56. Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, Minasian LM, Denicoff AM, O'Mara AM, Fisch MJ, Chauhan C, Aaronson NK, Coens C, Bruner DW. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014 Jul; 106(7): Epub 2014 Jul 8.
    View PubMed
  57. Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Santillana S, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith IE, Boyle F, Xu B, Gomez HL, Gelber RD, Perez EA. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014 Jun 20; 32 (18_suppl):LBA4
    View PubMed
  58. Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 2014 Jun 12; 123 (24):3803-10 Epub 2014 Feb 19
    View PubMed
  59. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, Hawse JR, Henry TJ, Barrett MT, Cunliffe HE, Pockaj BA. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 2014 Feb; 21 (2):361-7 Epub 2013 Sept 18
    View PubMed
  60. McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat 2014 Feb; 143 (3):485-92 Epub 2014 Jan 07
    View PubMed
  61. Patel SH, Hinni ML, Hayden RE, Wong WW, Dueck AC, Zarka MA, Curtis KK, Halyard MY. Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: the Mayo Clinic Arizona experience. Head Neck 2014 Feb; 36 (2):220-5 Epub 2013 Mar 26
    View PubMed
  62. Stonnington CM, Chen K, Lee W, Locke DE, Dueck AC, Liu X, Roontiva A, Fleisher AS, Caselli RJ, Reiman EM. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement 2014 Jan; 10 (1):e1-8 Epub 2013 Apr 11
    View PubMed
  63. Caselli RJ, Locke DE, Dueck AC, Knopman DS, Woodruff BK, Hoffman-Snyder C, Rademakers R, Fleisher AS, Reiman EM. The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement 2014 Jan; 10 (1):84-92 Epub 2013 Mar 26
    View PubMed
  64. Grover ML, Edwards FD, Chang YH, Cook CB, Behrens MC, Dueck AC. Fracture risk perception study: patient self-perceptions of bone health often disagree with calculated fracture risk. Womens Health Issues 2014 Jan-Feb; 24 (1):e69-75
    View PubMed
  65. Locke DE, Dueck AC, Stonnington CM, Knopman DS, Geda YE, Caselli RJ. Depressive symptoms in healthy apolipoprotein E epsilon4 carriers and noncarriers: a longitudinal study. J Clin Psychiatry 2013 Dec; 74 (12):1256-61
    View PubMed
  66. Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res 2013 Oct 15; 19 (20):5798-807 Epub 2013 Aug 21
    View PubMed
  67. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol 2013 Oct; 24 (10):2548-54 Epub 2013 June 24
    View PubMed
  68. Dueck AC, Nagi Reddy SK, Verona PM, Cook CB. Breast cancer patients with diabetes mellitus: Defining the population and assessing outcomes. J Clin Oncol 2013 Sep 10; 31 (26_suppl):137
    View PubMed
  69. Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1167-74. Epub 2013 May 7
    View PubMed
  70. Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer 2013 Aug 1; 119 (15):2675-82 Epub 2013 June 06
    View PubMed
  71. Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer 2013 Jul 1; 119 (13):2447-54 Epub 2013 Apr 12
    View PubMed
  72. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 2013 Jun 10; 31 (17):2115-22 Epub 2013 May 06
    View PubMed
  73. Reilly CM, Bruner DW, Mitchell SA, Minasian LM, Basch E, Dueck AC, Cella D, Reeve BB. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013 Jun; 21(6):1525-50. Epub 2013 Jan 12.
    View PubMed
  74. Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat 2013 Apr; 138 (2):427-35 Epub 2013 Mar 12
    View PubMed
  75. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013 Feb; 138 (1):99-108 Epub 2013 Feb 19
    View PubMed
  76. Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF, CPRO (Assessing. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer. 2013 Jan 15; 119(2):411-20. Epub 2012 Aug 28.
    View PubMed
  77. Zhang W, Johnston JA, Ross MA, Sanniec K, Gleason EA, Dueck AC, Santello M. Effects of carpal tunnel syndrome on dexterous manipulation are grip type-dependent. PLoS One. 2013; 8(1):e53751. Epub 2013 Jan 10.
    View PubMed
  78. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer 2012 Dec; 12 (6):387-91 Epub 2012 Oct 17
    View PubMed
  79. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012 Nov 20; 30 (33):4098-103 Epub 2012 Oct 15
    View PubMed
  80. Karlin NJ, Dueck AC, Cook CB. Cancer with diabetes: prevalence, metabolic control, and survival in an academic oncology practice. Endocr Pract. 2012 Nov-Dec; 18(6):898-905.
    View PubMed
  81. Caselli RJ, Dueck AC, Huentelman MJ, Lutz MW, Saunders AM, Reiman EM, Roses AD. Longitudinal modeling of cognitive aging and the TOMM40 effect. Alzheimers Dement 2012 Nov; 8 (6):490-5
    View PubMed
  82. Karlin NJ, Dueck AC. Metastatic breast cancer and the elderly: A single institution, retrospective review. J Clin Oncol 2012 Sep 20; 30 (27_suppl):55
    View PubMed
  83. McGhan LJ, Dueck AC, Gray RJ, Wasif N, McCullough AE, Pockaj BA. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2012 Sep 1; 106(3):254-9. Epub 2011 Oct 27.
    View PubMed
  84. Haakinson DJ, Leeds SG, Dueck AC, Gray RJ, Wasif N, Stucky CC, Northfelt DW, Apsey HA, Pockaj B. The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012 Sep; 19(9):3012-8. Epub 2012 Mar 27.
    View PubMed
  85. Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, Karis JP, Smith KA, Coons SW, Nakaji P, Spetzler RF, Feuerstein BG, Debbins J, Baxter LC. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol. 2012 Jul; 14(7):919-30. Epub 2012 May 03.
    View PubMed
  86. Ma I, Dueck A, Gray R, Wasif N, Giurescu M, Lorans R, Pizzitola V, Pockaj B. Clinical and self breast examination remain important in the era of modern screening. Ann Surg Oncol. 2012 May; 19(5):1484-90. Epub 2011 Dec 08.
    View PubMed
  87. McGhan LJ, Dueck AC, Pockaj BA, Gray RJ, Bagaria SP, Wasif N. Validation of a gastric cancer nomogram using a U.S. cancer registry. J Clin Oncol 2012 Feb; 30 (4_suppl):13
    View PubMed
  88. Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCOCAP HER2-positivity criteria. J Natl Cancer Inst 2012 Jan 18; 104 (2):159-62 Epub 2011 Dec 02
    View PubMed
  89. Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, Smith KA, Shapiro WR, Pinnaduwage DS, Coons SW, Nakaji P, Debbins J, Feuerstein BG, Baxter LC. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012 Jan; 33(1):69-76. Epub 2011 Nov 17.
    View PubMed
  90. Paripati HR, Karlin NJ, Schild SE, Vora SA, Dueck AC, Ross HJ. Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis. Journal of Geriatric Oncology. 2012; 3(2):104-10.
  91. Zhang W, Johnston JA, Ross MA, Coakley BJ, Gleason EA, Dueck AC, Santello M. Effects of carpal tunnel syndrome on adaptation of multi-digit forces to object mass distribution for whole-hand manipulation. J Neuroeng Rehabil. 2012; 9:83. Epub 2012 Nov 21.
    View PubMed
  92. Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, Wright K, Dueck AC, Jameson G, Von Hoff DD. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer 2012; 3:345-53 Epub 2012 Aug 17
    View PubMed
  93. Egnatios GL, Dueck AC, Macdonald JB, Laman SD, Warschaw KE, DiCaudo DJ, Nemeth SA, Sekulic A, Gray RJ, Wasif N, Pockaj BA. The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma. Am J Surg. 2011 Dec; 202(6):771-7; discussion 777-8. Epub 2011 Oct 13.
    View PubMed
  94. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
    View PubMed
  95. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011 Nov 1; 117 (21):4869-77 Epub 2011 Apr 08
    View PubMed
  96. Billar JA, Dueck AC, Gray RJ, Wasif N, Pockaj BA. Preoperative predictors of nipple-areola complex involvement for patients undergoing mastectomy for breast cancer. Ann Surg Oncol. 2011 Oct; 18(11):3123-8. Epub 2011 Aug 23.
    View PubMed
  97. Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS, Hamawi K, Khamash H, Moss AA, Mulligan DC, Katariya N, Knowler WC. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care 2011 Oct; 34 (10):2141-5
    View PubMed
  98. Sheikh F, Pockaj B, Wasif N, Dueck A, Gray RJ. Positive margins after breast-conserving therapy: localization technique or tumor biology? Am J Surg 2011 Sep; 202 (3):281-5 Epub 2011 May 19
    View PubMed
  99. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011 Jul 14; 118(2):401-8. Epub 2011 May 02.
    View PubMed
  100. Craft RO, Rebecca AM, Flahive C, Casey WJ, Dueck A, Harold KL. Does size matter? Technical considerations of a regenerative tissue matrix for use in reconstructive surgery. Can J Plast Surg. 2011 Summer; 19(2):51-2.
    View PubMed
  101. Stonnington CM, Locke DE, Dueck AC, Caselli RJ. Anxiety affects cognition differently in healthy apolipoprotein E epsilon4 homozygotes and non-carriers. J Neuropsychiatry Clin Neurosci. 2011 Summer; 23(3):294-9.
    View PubMed
  102. Scherber RM, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson BI, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Maldonado N, Sackmann F, Muxi P, Hernandez-Maraver D, Kiladjian J, Mesa RA. Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients. J Clin Oncol 2011 May 20; 29 (15_suppl):6610
    View PubMed
  103. Northfelt DW, Dueck AC, Flynn TP, Zander PJ, Stella PJ, Melnik M, Pavey ES, Perez EA. Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. J Clin Oncol 2011 May 20; 29 (15_suppl):1126
    View PubMed
  104. Perez EA, Dueck AC, Reinholz MM, Chen B, Geiger X, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, McCullough AE. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 2011 May 20; 29 (15_suppl):10504
    View PubMed
  105. Reinholz MM, Dueck AC, Chen B, Geiger X, McCullough AE, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, Perez EA. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 2011 May 20; 29 (15_suppl):10503
    View PubMed
  106. Dueck AC, Sargent DJ, Novotny PJ, Decker PA, Nelson H, Qin R, Sloan JA. Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. J Clin Oncol 2011 May 20; 29 (15_suppl):6130
    View PubMed
  107. Karlin NJ, Dueck AC, Cook C. Cancer with diabetes: Prevalence, metabolic control, and survival in a general oncology practice. J Clin Oncol 2011 May 20; 29 (15_suppl):1542
    View PubMed
  108. Caselli RJ, Dueck AC, Locke DE, Hoffman-Snyder CR, Woodruff BK, Rapcsak SZ, Reiman EM. Longitudinal modeling of frontal cognition in APOE epsilon4 homozygotes, heterozygotes, and noncarriers. Neurology 2011 Apr 19; 76 (16):1383-8
    View PubMed
  109. Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM. Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology 2011 Mar 22; 76 (12):1078-84 Epub 2011 Feb 16
    View PubMed
  110. Grover M, Mookadam M, Armas D, Bozarth C, Castleberry T, Gannon M, Webb D, Dueck A. Identifying patients at risk for obstructive sleep apnea in a primary care practice. J Am Board Fam Med. 2011 Mar-Apr; 24(2):152-60.
    View PubMed
  111. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011 Feb 20; 29 (6):651-9 Epub 2011 Jan 18
    View PubMed
  112. Ferreira S, Shunk D, Collofello J, MacKulak G, Dueck A. Reducing the risk of requirements volatility: Findings from an empirical survey. Journal of Software Maintenance and Evolution. 2011; 23(5):375-93.
  113. Curtis KK, Ashman JB, Beauchamp CP, Schwartz AJ, Callister MD, Dueck AC, Gunderson LL, Fitch TR. Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities. Radiat Oncol. 2011; 6:91. Epub 2011 Aug 09.
    View PubMed
  114. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011; 16(10):1359-66. Epub 2011 Sep 20.
    View PubMed
  115. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011; 2:538-43. Epub 2011 Nov 01.
    View PubMed
  116. Zhang W, Johnston JA, Ross MA, Smith AA, Coakley BJ, Gleason EA, Dueck AC, Santello M. Effects of carpal tunnel syndrome on adaptation of multi-digit forces to object weight for whole-hand manipulation. PLoS One. 2011; 6(11):e27715. Epub 2011 Nov 16.
    View PubMed
  117. Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(R) platform. BMC Med Genomics 2010 Dec 20; 3:60
    View PubMed
  118. Stucky CC, Gray RJ, Dueck AC, Wasif N, Laman SD, Sekulic A, Pockaj BA. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg. 2010 Dec; 200(6):770-4; discussion 774-5.
    View PubMed
  119. Haakinson DJ, Stucky CC, Dueck AC, Gray RJ, Wasif N, Apsey HA, Pockaj B. A significant number of women present with palpable breast cancer even with a normal mammogram within 1 year. Am J Surg 2010 Dec; 200 (6):712-7; discussion 717-8
    View PubMed
  120. Sprangers MA, Sloan JA, Barsevick A, Chauhan C, Dueck AC, Raat H, Shi Q, Van Noorden. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res. 2010 Dec; 19(10):1395-403. Epub 2010 Oct 14.
    View PubMed
  121. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010 Oct 01; 28 (28):4307-15 Epub 2010 Aug 09
    View PubMed
  122. Stucky CC, Gray RJ, Wasif N, Dueck AC, Pockaj BA. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:330-7. Epub 2010 Sep 19.
    View PubMed
  123. Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:384-90. Epub 2010 Sep 19.
    View PubMed
  124. Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, Gray RJ, McLaughlin SA, Northfelt DW, Sticca RP, Jakub JW, Perez EA. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol 2010 Sep; 17 (9):2419-26 Epub 2010 Mar 16
    View PubMed
  125. Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010 Sep; 5 (9):1669-75 Epub 2010 June 17
    View PubMed
  126. Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lonnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A, Lingle WL. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone 2010 Jul; 47 (1):12-22 Epub 2010 Mar 15
    View PubMed
  127. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, Mattar BI, Loprinzi CL. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010 May; 68(2):234-9. Epub 2009 Aug 08.
    View PubMed
  128. Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM Jr, Fuloria J, Flynn PJ, Dentchev T, Loprinzi CL. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer 2010 Mar; 18 (3):321-8 Epub 2009 May 27
    View PubMed
  129. Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 2010 Feb; 21 (2):269-74 Epub 2009 Nov 09
    View PubMed
  130. Hu LS, Baxter LC, Pinnaduwage DS, Paine TL, Karis JP, Feuerstein BG, Schmainda KM, Dueck AC, Debbins J, Smith KA, Nakaji P, Eschbacher JM, Coons SW, Heiserman JE. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010 Jan; 31 (1):40-8 Epub 2009 Sept 12
    View PubMed
  131. Grover M, Anderson M, Gupta R, Haden M, Hartmark-Hill J, Morski LM, Sarmiento P, Dueck A. Increased osteoporosis screening rates associated with the provision of a preventive health examination. J Am Board Fam Med. 2009 Nov-Dec; 22(6):655-62.
    View PubMed
  132. Stucky CC, McLaughlin SA, Dueck AC, Gray RJ, Giurescu ME, Carpenter SG, Grimsby GM, Apsey HA, Pockaj BA. Does magnetic resonance imaging accurately predict residual disease in breast cancer? Am J Surg. 2009 Oct; 198(4):547-52.
    View PubMed
  133. Grimsby GM, Gray R, Dueck A, Carpenter S, Stucky CC, Aspey H, Giurescu ME, Pockaj B. Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am J Surg. 2009 Oct; 198(4):500-4.
    View PubMed
  134. Carpenter SG, Stucky CC, Dueck AC, Grimsby G, Giurescu M, Apsey H, Gray RJ, Pockaj BA. Scientific Presentation Award: The impact of magnetic resonance imaging on surgical treatment of invasive breast cancer. Am J Surg. 2009 Oct; 198(4):475-81.
    View PubMed
  135. Shrestha B, Sekiguchi H, Colby TV, Graziano P, Aubry MC, Smyrk TC, Feldman AL, Cornell LD, Ryu JH, Chari ST, Dueck AC, Yi ES. Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol. 2009 Oct; 33(10):1450-62.
    View PubMed
  136. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DE, Snyder CH, Alexander GE, Rademakers R, Reiman EM. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 2009 Jul 16; 361 (3):255-63
    View PubMed
  137. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009 Jun 01; 27 (16):2638-44 Epub 2009 Apr 06
    View PubMed
  138. Pockaj BA, Degnim AC, Boughey JC, Gray RJ, McLaughlin SA, Dueck AC, Perez EA, Halyard MY, Frost MH, Cheville AL, Sloan JA. Quality of life after breast cancer surgery: What have we learned and where should we go next? J Surg Oncol. 2009 Jun 1; 99(7):447-55.
    View PubMed
  139. Sprangers MA, Sloan JA, Veenhoven R, Cleeland CS, Halyard MY, Abertnethy AP, Baas F, Barsevick AM, Bartels M, Boomsma DI, Chauhan C, Dueck AC, Frost MH, Hall P, Klepstad P, Martin NG, Miaskowski C, Mosing M, Movsas B, Van Noorden, Patrick DL, Pedersen NL, Ropka ME, Shi Q, Shinozaki G, Singh JA, Yang P, Zwinderman AH. The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet. 2009 Jun; 12(3):301-11.
    View PubMed
  140. Sukov WR, Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. J Clin Oncol 2009 May 20; 27 (15_suppl):520
    View PubMed
  141. Moreno-Aspitia A, Hillman DW, Dueck AC, Carney WP, Lingle WL, Tenner KS, Lafky JM, Reinholz MM, Kutteh LA, Perez EA. Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol 2009 May 20; 27 (15_suppl):539
    View PubMed
  142. Paripati H, Tong W, Karlin NJ, Dueck AC, Ross HJ. Treatment and outcomes of elderly versus younger patients with advanced NSCLC at Mayo Clinic Arizona (MCA). J Clin Oncol 2009 May 20; 27 (15_suppl):e19047
    View PubMed
  143. Reinholz MM, Kitzmann KA, Hobday TJ, Northfelt DW, LaPlant B, Allred JB, Dueck AC, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437. J Clin Oncol 2009 May 20; 27 (15_suppl):11095
    View PubMed
  144. McCullough A, Dueck A, Chen B, Reinholz M, Wiktor A, Lingle W, Jenkins R, Perez E. HER-2 central confirmatory testing using ASCO/CAP guidelines for trastuzumab/lapatinib trial MCCR RC0639. J Clin Oncol 2009 May 20; 27 (15_suppl):e11527
    View PubMed
  145. Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD 3rd, Kottschade L, Fitch TR. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009 Mar; 20 (3):542-9 Epub 2009 Jan 06
    View PubMed
  146. Pipe TB, Bortz JJ, Dueck A, Pendergast D, Buchda V, Summers J. Nurse leader mindfulness meditation program for stress management: a randomized controlled trial. J Nurs Adm. 2009 Mar; 39(3):130-7.
    View PubMed
  147. Conley SP, Humphreys MR, Desai PJ, Castle EP, Dueck AC, Ferrigni RG, Andrews PE. Laparoscopic radical nephrectomy for very large renal tumors (> or =10 cm): is there a size limit? J Endourol 2009 Jan; 23 (1):57-61
    View PubMed
  148. Halyard M, Pisansky T, Dueck A, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez E. Radiotherapy and Adjuvant Trastuzumab in Stage I-IIA Breast Cancer: Tolerability and Adverse Event Data From the North Central Cancer Treatment Group Phase I Trial N9831. J Clin Oncol. 2009; 27:2638-44.
    View PubMed
  149. Carpenter S, Pockaj B, Dueck A, Gray R, Kurtz D, Sekulic A, Casey W. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg. 2008 Dec; 196(6):834-42; discussion 842-3.
    View PubMed
  150. Suman VJ, Dueck A, Sargent DJ. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest. 2008 Jun; 26(5):439-44.
    View PubMed
  151. Moreno-Aspitia A, Dueck AC, Lingle WL, Kutteh L, Tenner K, Davidson NE, Martino S, Kaufman P, Carney WP, Perez EA. Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol 2008 May 20; 26 (15_suppl):529
    View PubMed
  152. Dueck AC, Atherton PJ, Liu H, Hines SL, Loprinzi CL, Perez EA, Tan AD, Burger K, Zhao X, Diekmann B, Sloan JA. Endpoint comparison for osteoporosis assessment in cancer control studies (N02C1 and N03CC). J Clin Oncol 2008 May 20; 26 (15_suppl):6627
    View PubMed
  153. Reinholz MM, Dueck AC, Lingle WL, Allen Ziegler KL, Wiktor AE, Paik S, Jenkins RB, Perez EA. The concordance between NCCTG's and NSABP's C-myc FISH assays. J Clin Oncol 2008 May 20; 26 (15_suppl):22110
    View PubMed
  154. Paripati H, Stewart AK, Fonseca R, Dueck AC, Slack JL, Reeder CB, Leis J, Bergsagel PL, Torloni AS. Impact of lenalidomide therapy on stem cell mobilization in myeloma. J Clin Oncol 2008 May 20; 26 (15_suppl):8543
    View PubMed
  155. Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, Morrow GR, Dueck AC, National Cancer Institute. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol. 2007 Nov 10; 25(32):5070-7.
    View PubMed
  156. Dueck AC, Sloan JA. Meeting on the FDA draft guidance on patient-reported outcomes. Value Health. 2007 Nov-Dec; 10 Suppl 2:S64-5.
    View PubMed
  157. Sloan JA, Dueck AC, Erickson PA, Guess H, Revicki DA, Santanello NC, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Analysis and interpretation of results based on patient-reported outcomes. Value Health. 2007 Nov-Dec; 10 Suppl 2:S106-15.
    View PubMed
  158. Sloan JA, Halyard MY, Frost MH, Dueck AC, Teschendorf B, Rothman ML. The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomes. Value Health. 2007 Nov-Dec; 10(Suppl 2):S59-63.
    View PubMed
  159. Revicki DA, Erickson PA, Sloan JA, Dueck A, Guess H, Santanello NC, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Interpreting and reporting results based on patient-reported outcomes. Value Health. 2007 Nov-Dec; 10 Suppl 2:S116-24.
    View PubMed
  160. Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Aug 1; 110(3):489-98.
    View PubMed
  161. Mularski RA, Rosenfeld K, Coons SJ, Dueck A, Cella D, Feuer DJ, Lipscomb J, Karpeh MS Jr, Mosich T, Sloan JA, Krouse RS. Measuring outcomes in randomized prospective trials in palliative care. J Pain Symptom Manage. 2007 Jul; 34(1 Suppl):S7-S19. Epub 2007 May 25.
    View PubMed
  162. Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007 Jan 20; 25(3):308-12. Epub 2006 Dec 04.
    View PubMed
  163. Halyard MY, Frost MH, Dueck A, Sloan JA. Is the use of QOL data really any different than other medical testing? Curr Probl Cancer. 2006 Nov-Dec; 30(6):261-71.
    View PubMed
  164. Dueck A, Novotny PJ. Dealing with multiple endpoints. Curr Probl Cancer. 2006 Nov-Dec; 30(6):298-306.
    View PubMed
  165. Halyard MY, Frost MH, Dueck A. Integrating QOL assessments for clinical and research purposes. Curr Probl Cancer. 2006 Nov-Dec; 30(6):319-30.
    View PubMed
  166. Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006 Oct; 14(10):988-98. Epub 2006 Jun 23.
    View PubMed
  167. Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, Perez EA. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol 2006 Jun 20; 24 (18_suppl):523
    View PubMed
  168. Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Carlson MD, Duane SF, Corso SW. Phase III randomized trial to evaluate the use of gabapentin alone vs with continuing an antidepressant in women failing an antidepressant for the treatment of hot flashes: North Central Cancer Treatment Group Study N00C3. J Clin Oncol 2006 Jun 20; 24 (18_suppl):526
    View PubMed
  169. Garrison LP Jr, Perez EA, Dueck A, Lalla D, Paton V, Lubeck D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. J Clin Oncol 2006 Jun 20; 24 (18_suppl):6023
    View PubMed
  170. Dueck A, Atherton P, Tan A, Sloan J. How much missing data is too much? A single study exploration. J Clin Oncol 2006 Jun 20; 24 (18_suppl):6116
    View PubMed
  171. Kamath C, Dueck A. Incorporating clinical significance into a study. Curr Probl Cancer. 2005 Nov-Dec; 29(6):306-16.
    View PubMed
  172. Huntington JL, Dueck A. Handling missing data. Curr Probl Cancer. 2005 Nov-Dec; 29(6):317-25.
    View PubMed
  173. Mandrekar S, Dueck A. Future directions in QOL research. Curr Probl Cancer. 2005 Nov-Dec; 29(6):343-51.
    View PubMed
  174. Dueck A, Lohr S. Robust estimation of multivariate covariance components. Biometrics. 2005 Mar; 61(1):162-9.
    View PubMed
  175. Sloan J, Frost M, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D. The Clinical Significance of Quality of Life Assessments in Oncology: A Summary for Clinicians Cancer. 2005.
    View PubMed
  176. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat. 2004 Feb; 14(1):73-96.
    View PubMed